{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:02:39Z","timestamp":1780668159162,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ijcard.2024.132660","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T22:15:56Z","timestamp":1729289756000},"page":"132660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Downstream cangrelor versus upstream ticagrelor in patients with ST-segment elevation myocardial infarction: A propensity score-matched analysis"],"prefix":"10.1016","volume":"418","author":[{"given":"Antonio","family":"Greco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Scalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Laudani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sara","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Sammartino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piera","family":"Capranzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"38","key":"10.1016\/j.ijcard.2024.132660_bb0005","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.ijcard.2024.132660_bb0010","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.ijcard.2024.132660_bb0015","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization","volume":"79","author":"Lawton","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.ijcard.2024.132660_bb0020","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/14656566.2023.2171788","article-title":"Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"24","author":"Greco","year":"2023","journal-title":"Expert. Opin. Pharmacother."},{"issue":"11","key":"10.1016\/j.ijcard.2024.132660_bb0025","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus Clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"29","key":"10.1016\/j.ijcard.2024.132660_bb0030","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.2174\/1381612822666160601111155","article-title":"Oral antiplatelet treatment in STEMI: current practice and future considerations","volume":"22","author":"Xanthopoulou","year":"2016","journal-title":"Curr. Pharm. Des."},{"issue":"11","key":"10.1016\/j.ijcard.2024.132660_bb0035","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/17425255.2023.2272595","article-title":"Evaluating the pharmacokinetic and pharmacodynamic impact of different modes of ticagrelor administration","volume":"19","author":"Spagnolo","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"13","key":"10.1016\/j.ijcard.2024.132660_bb0040","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022125","article-title":"Cangrelor: clinical data, contemporary use, and future perspectives","volume":"10","author":"De Luca","year":"2021","journal-title":"J. Am. Heart Assoc."},{"issue":"24","key":"10.1016\/j.ijcard.2024.132660_bb0045","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.ijcard.2024.132660_bb0050","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.ijcard.2024.132660_bb0055","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ijcard.2024.132660_bb0060","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"40","author":"Thygesen","year":"2019","journal-title":"Eur. Heart J."},{"issue":"24","key":"10.1016\/j.ijcard.2024.132660_bb0065","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289","article-title":"Standardized end point definitions for coronary intervention trials: the academic research Consortium-2 consensus document","volume":"137","author":"Garcia-Garcia","year":"2018","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.ijcard.2024.132660_bb0070","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.ijcard.2024.132660_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10132829","article-title":"Cangrelor use in routine practice: a two-center experience","volume":"10","author":"van der Sangen","year":"2021","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.ijcard.2024.132660_bb0080","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oead076","article-title":"Safety of cangrelor and transition to oral P2Y(12) inhibitors in patients undergoing percutaneous coronary intervention: the ARCANGELO study","volume":"3","author":"De Luca","year":"2023","journal-title":"Eur. Heart J. Open"},{"issue":"1","key":"10.1016\/j.ijcard.2024.132660_bb0085","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-37084-2","article-title":"Comparative effectiveness of Cangrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: an observational investigation from the M.O.Ca. Registry","volume":"13","author":"Pepe","year":"2023","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ijcard.2024.132660_bb0090","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ehjcvp\/pvz002","article-title":"Clinical use of cangrelor: nationwide experience from the Swedish coronary angiography and angioplasty registry (SCAAR)","volume":"5","author":"Grimfj\u00e4rd","year":"2019","journal-title":"Eur. Heart J. Cardiovas. Pharmaco."},{"issue":"10","key":"10.1016\/j.ijcard.2024.132660_bb0095","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1161\/CIRCULATIONAHA.115.020829","article-title":"Consistent reduction in Periprocedural myocardial infarction with Cangrelor as assessed by multiple definitions: findings from CHAMPION PHOENIX (Cangrelor versus standard therapy to achieve optimal Management of Platelet Inhibition)","volume":"134","author":"Cavender","year":"2016","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ijcard.2024.132660_bb0100","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/ehjacc\/zuae014","article-title":"Periprocedural myocardial infarction and injury","volume":"13","author":"Spagnolo","year":"2024","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"issue":"20","key":"10.1016\/j.ijcard.2024.132660_bb0105","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.jcin.2023.08.037","article-title":"Short dual antiplatelet therapy in high bleeding risk patients: 1 month or 3 months?","volume":"16","author":"Capodanno","year":"2023","journal-title":"JACC Cardiovasc. Interv."},{"issue":"1","key":"10.1016\/j.ijcard.2024.132660_bb0110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jacasi.2022.10.008","article-title":"Shortening dual antiplatelet therapy duration in high-risk patients undergoing percutaneous coronary intervention","volume":"3","author":"Greco","year":"2023","journal-title":"JACC Asia"},{"issue":"11","key":"10.1016\/j.ijcard.2024.132660_bb0115","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/eurheartj\/ehac713","article-title":"Dual antiplatelet therapy in patients at high bleeding risk: less is more-more or less","volume":"44","author":"Capodanno","year":"2023","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.ijcard.2024.132660_bb0120","article-title":"Risk stratification for bleeding in the elderly with acute coronary syndrome: not so simple","volume":"118","author":"Capodanno","year":"2018","journal-title":"Thromb. Haemost."},{"issue":"16","key":"10.1016\/j.ijcard.2024.132660_bb0125","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.jcin.2017.07.009","article-title":"Cangrelor use in cardiogenic shock: a single-center real-world experience","volume":"10","author":"Vaduganathan","year":"2017","journal-title":"J. Am. Coll. Cardiol. Intv."},{"key":"10.1016\/j.ijcard.2024.132660_bb0130","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.resuscitation.2019.02.008","article-title":"Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: a global, multicenter, matched pair analysis with oral P2Y(12) inhibition from the IABP-SHOCK II trial","volume":"137","author":"Droppa","year":"2019","journal-title":"Resuscitation"},{"issue":"7","key":"10.1016\/j.ijcard.2024.132660_bb0135","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/ehjacc\/zuad041","article-title":"Cangrelor in patients with percutaneous coronary intervention for acute myocardial infarction after cardiac arrest and\/or with cardiogenic shock","volume":"12","author":"Zeymer","year":"2023","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"issue":"8","key":"10.1016\/j.ijcard.2024.132660_bb0140","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/14740338.2023.2245331","article-title":"Gender differences in efficacy and safety of antiplatelet strategies for acute coronary syndromes","volume":"22","author":"Occhipinti","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"issue":"4","key":"10.1016\/j.ijcard.2024.132660_bb0145","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/14779072.2021.1902806","article-title":"Differences in coronary artery disease and outcomes of percutaneous coronary intervention with drug-eluting stents in women and men","volume":"19","author":"Greco","year":"2021","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"issue":"5","key":"10.1016\/j.ijcard.2024.132660_bb0150","doi-asserted-by":"crossref","first-page":"590","DOI":"10.23736\/S2724-5683.22.06167-1","article-title":"In-hospital outcomes in nonagenarian patients undergoing primary percutaneous coronary intervention","volume":"71","author":"Angelini","year":"2023","journal-title":"Minerva Cardiol Angiol."},{"issue":"2","key":"10.1016\/j.ijcard.2024.132660_bb0155","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ccd.30696","article-title":"Predictors of target lesion failure after treatment of left main, bifurcation, or chronic total occlusion lesions with ultrathin-strut drug-eluting coronary stents in the ULTRA registry","volume":"102","author":"de Filippo","year":"2023","journal-title":"Catheter. Cardiovasc. Interv."},{"issue":"01","key":"10.1016\/j.ijcard.2024.132660_bb0160","doi-asserted-by":"crossref","first-page":"009","DOI":"10.1055\/s-0038-1676612","article-title":"The conundrum surrounding racial differences on Ischaemic and bleeding risk with dual anti-platelet therapy","volume":"119","author":"Greco","year":"2019","journal-title":"Thromb. Haemost."},{"issue":"15","key":"10.1016\/j.ijcard.2024.132660_bb0165","first-page":"1269","article-title":"Cangrelor for comatose survivors of out-of-hospital cardiac arrest undergoing percutaneous coronary intervention: the CANGRELOR-OHCA study","volume":"18","author":"Kordis","year":"2023","journal-title":"EuroIntervention"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324012828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324012828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T21:13:16Z","timestamp":1737580396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527324012828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":33,"alternative-id":["S0167527324012828"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132660","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Downstream cangrelor versus upstream ticagrelor in patients with ST-segment elevation myocardial infarction: A propensity score-matched analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132660","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"132660"}}